Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the Antibody Engineering and Therapeutics Conference December 11-15, 2017 in San Diego, CA. John Burke, PhD, will present Model Aided Drug Invention (MADI) case studies on Thursday, December 14, 2017 at 12:00 p.m. In addition to speaking at the event, Applied BioMath is also participating as a scientific briefing sponsor. 

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in FierceBiotech’s second Drug Development Forum occurring September 25-27, 2017 in Boston, MA. Applied BioMath will be a sponsor as well as presenter at the event.

In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO at Applied BioMath discusses how Applied BioMath is modernizing drug discovery, drug development, and clinical trials by applying quantitative systems pharmacology (QSP), mathematical modeling and machine learning techniques to drug research and development. "We help predict the failures much earlier - with the killer experiment, to help reduce late stage attrition rates," said Dr. John Burke. "This helps our collaborators prioritize their resources and their experiments."

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the upcoming American Conference on Pharmacometrics (ACoP) occurring October 15-18, 2017 in Fort Lauderdale, FL. Applied BioMath will be a conference sponsor, exhibitor, and poster presenter. Applied BioMath’s posters will highlight several examples of model-aided drug invention (MADI) by presenting case studies in immuno-oncology, osteoarthritis, and antibody-drug conjugates. More specifically, they will show:

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the World Bispecific Summit occurring September 26-28, 2017 in Boston, MA. In addition to sponsoring and exhibiting at the 8th annual summit, Dr.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in an upcoming quantitative systems pharmacology (QSP) event hosted by the Pharmaceutical and BioScience Society on September 29, 2017 in Boston, MA. Applied BioMath is the sole major sponsor of the day-long event as well as a presenter of two case studies in immuno-oncology and osteoarthritis.   

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced an extension of their collaboration with Zymeworks Inc. for quantitative systems pharmacology (QSP) support for antibody drug conjugate therapeutics intended for the treatment of cancer.

Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that Louis J. Latino, Jr. is joining its team as Senior Vice President of Business Development.  In this role, Lou will lead the Applied BioMath business development team and continue to develop the company's growth strategy in the biotechnology and pharmaceutical industry.

Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, announced their collaboration with Tusk Therapeutics for quantitative systems pharmacology (QSP) modeling and analysis to enable preclinical candidate selection in immuno-oncology. Applied BioMath leveraged its proprietary mechanistic modeling platform to develop a QSP model of one of Tusk Therapeutics' targets and antibody candidates, then analyzed this model to identify optimal drug properties to aid preclinical candidate selection.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, will present at Drug Development Boot Camp on November 16-17, 2016 at The Harvard Club in Boston, MA. This intensive two-day program, organized by Harvard University and Speid & Associates, allows executive level biotech and pharmaceutical scientists to share successes and challenges of the drug development process.

Updated 12/13/2016: Applied BioMath awarded Best Poster award at World ADC 2016!

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced that they will deliver a presentation and poster at the 7th annual World ADC conference on the use of quantitative systems pharmacology (QSP) modeling to understand the pharmacokinetics (PK) of antibody drug conjugate (ADC) therapeutics.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the Annual e:Med Meeting on Systems Medicine 2016 in Kiel, Germany on October 4-6, 2016. Dr.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug invention, today announced an agreement with Jounce Therapeutics for clinical pharmacology and quantitative systems pharmacology (QSP) modeling and simulation support for Phase 1 clinical trials.

Applied BioMath will:

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, has been named a Top 10 small, high growth business in the Greater Boston area by the Greater Boston Chamber of Commerce. This award honors businesses that demonstrate achievement in management, workplace excellence, product innovation, and social responsibility.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, today announced their participation in the SIAM Conference on the Life Sciences which was held July 11-14, 2016 in Boston, MA.

In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO of Applied BioMath, discusses advanced mathematical dynamical systems pharmacology modeling and biology applications for drug discovery, development and clinical trials. "Our mathematical and biological rigor allows us to provide deep biological insights years earlier than they would surface in the clinic," said Dr. John M. Burke. "This is what sets us apart from previous efforts and also from competitors."

Dr. John Burke, Co-Founder, President, and CEO of Applied BioMath, LLC was recently featuerd in CEO/CFO magazine. Lynn Fosse, Senior Editor of CEOCFO Magazine interviewed Dr. Burke to learn about how Applied BioMath is revolutionizing drug invention, why its technology is different than anything offered today, and examples where Applied BioMath helped optimize and accelerate drug development.

Read Dr. Burke's interview in CEO/CFO Magazine